Glen Eagle Advisors, LLC Roivant Sciences Ltd. Transaction History
Glen Eagle Advisors, LLC
- $603 Billion
- Q4 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 435 shares of ROIV stock, worth $4,432. This represents 0.0% of its overall portfolio holdings.
Number of Shares
435
Previous 435
-0.0%
Holding current value
$4,432
Previous $5.02 Million
2.51%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
332Shares Held
505MCall Options Held
573KPut Options Held
739K-
Qvt Financial LP New York, NY65.8MShares$670 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$632 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$487 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$449 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$360 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.18B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...